Brokerages Set Sanofi (NASDAQ:SNY) Target Price at $53.00

Shares of Sanofi (NASDAQ:SNY) have received a consensus rating of “Hold” from the ten research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $53.00.

A number of analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Sanofi in a research note on Friday, January 15th. They issued a “sell” rating for the company. UBS Group restated a “buy” rating on shares of Sanofi in a research note on Tuesday, January 19th. Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, February 10th. Finally, Barclays restated an “equal weight” rating on shares of Sanofi in a research note on Tuesday.

A number of institutional investors have recently bought and sold shares of SNY. Sei Investments Co. boosted its holdings in Sanofi by 1.6% during the third quarter. Sei Investments Co. now owns 340,509 shares of the company’s stock worth $17,081,000 after buying an additional 5,316 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in Sanofi by 1,498.2% during the fourth quarter. Kestra Advisory Services LLC now owns 172,094 shares of the company’s stock worth $8,322,000 after buying an additional 161,326 shares during the last quarter. Perigon Wealth Management LLC bought a new position in Sanofi during the fourth quarter worth about $113,000. Oppenheimer Asset Management Inc. boosted its holdings in Sanofi by 7.7% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 201,127 shares of the company’s stock worth $9,773,000 after buying an additional 14,399 shares during the last quarter. Finally, Morris Retirement Advisors LLC bought a new position in Sanofi during the fourth quarter worth about $334,000. Institutional investors and hedge funds own 6.93% of the company’s stock.

Sanofi stock traded up $0.49 during mid-day trading on Monday, hitting $50.46. 4,509 shares of the company were exchanged, compared to its average volume of 2,575,668. The company has a quick ratio of 1.38, a current ratio of 1.85 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $47.96 and a 200 day moving average of $48.74. Sanofi has a 1-year low of $42.80 and a 1-year high of $55.00. The company has a market capitalization of $127.06 billion, a PE ratio of 21.35, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 4th. The company reported $0.73 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.88 by ($0.15). Sanofi had a net margin of 14.49% and a return on equity of 24.77%. The business had revenue of $9.38 billion during the quarter, compared to analyst estimates of $9.39 billion. During the same quarter last year, the business posted $1.34 earnings per share. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. Research analysts expect that Sanofi will post 3.49 earnings per share for the current year.

The company also recently declared an annual dividend, which will be paid on Wednesday, May 26th. Investors of record on Tuesday, May 4th will be issued a $1.9061 dividend. This is a boost from Sanofi’s previous annual dividend of $1.21. The ex-dividend date is Monday, May 3rd. This represents a yield of 3.2%. Sanofi’s dividend payout ratio (DPR) is currently 35.24%.

Sanofi Company Profile

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.

Read More: What is a blue-chip stock?

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.